Real-world data on adult t-cell leukemia/lymphoma in latin america: A study from the grupo de estudio latinoamericano de linfoproliferativos

Luis Malpica, Daniel J. Enriquez, Denisse A. Castro, Camila Peña, Henry Idrobo, Lorena Fiad, Maria Prates, Victoria Otero, Mirna Biglione, Milagros Altamirano, Gustavo Sandival-Ampuero, Ursula Aviles-Perez, Kelly Meza, Laura Aguirre-Martinez, Nancy Cristaldo, Juan L. Maradei, Luciana Guanchiale, Pablo Soto, Jose L. Viñuela, Maria E. CabreraSally Rose Paredes, Eloisa Riva, Marcos Di Stefano, Andrea Noboa, Juan A. Choque, Myrna Candelaria, Alana Von Glasenapp, Fabiola Valvert, Maria A. Torres-Viera, Jorge J. Castillo, Juan Carlos Ramos, Luis Villela, Brady E. Beltran

Producción científica: Contribución a una revistaArtículorevisión exhaustiva

14 Citas (Scopus)

Resumen

PURPOSE Adult T-cell leukemia/lymphoma (ATLL) is an aggressive disease caused by the human T-cell leukemia virus type 1. Real-world data of ATLL in Latin America are lacking. PATIENTS AND METHODS We analyzed patients with ATLL (acute, lymphomatous, chronic, and smoldering) encountered in 11 Latin American countries between 1995 and 2019. Treatment response was assessed according to the 2009 consensus report. Survival curves were estimated using the Kaplan-Meier method and log-rank test. RESULTS We identified 253 patients; 226 (lymphomatous: n = 122, acute: n = 73, chronic: n = 26, and smoldering: n = 5) had sufficient data for analysis (median age 57 years). Most patients with ATLL were from Peru (63%), Chile (17%), Argentina (8%), and Colombia (7%). Hypercalcemia was positively associated with acute type (57% v lymphomatous 27%, P = .014). The median survival times (months) were 4.3, 7.9, 21.1, and not reached for acute, lymphomatous, chronic, and smoldering forms, with 4-year survival rates of 8%, 22%, 40%, and 80%, respectively. First-line zidovudine (AZT)-interferon alfa (IFN) resulted in an overall response rate of 63% (complete response [CR] 24%) for acute. First-line chemotherapy yielded an overall response rate of 41% (CR 29%) for lymphomatous. CR rate was 42% for etoposide, cyclophosphamide, vincristine, doxorubicin, and prednisone versus 12% for cyclophosphamide, vincristine, doxorubicin, and prednisone-like regimen (P,.001). Progression-free survival at 1 year for acute type patients treated with AZT-IFN was 67%, whereas 2- year progression-free survival in lymphomatous type patients who achieved CR after chemotherapy was 77%. CONCLUSION This study confirms Latin American ATLL presents at a younger age and has a high incidence of lymphomatous type, low incidence of indolent subtypes, and worse survival rates as compared with Japanese patients. In aggressive ATLL, chemotherapy remains the preferred choice for lymphomatous favoring etoposidebased regimen (etoposide, cyclophosphamide, vincristine, doxorubicin, and prednisone), whereas AZT-IFN remains a good first-line option for acute subtype.

Idioma originalInglés
Páginas (desde-hasta)1151-1166
Número de páginas16
PublicaciónJCO Global Oncology
Volumen7
DOI
EstadoPublicada - 2021

Huella

Profundice en los temas de investigación de 'Real-world data on adult t-cell leukemia/lymphoma in latin america: A study from the grupo de estudio latinoamericano de linfoproliferativos'. En conjunto forman una huella única.

Citar esto